Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

VKTX - Viking Therapeutics

Discussion in 'Penny Stocks' started by StockJock-e, Apr 7, 2016.

  1. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,112
    Likes Received:
    1,570
    Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which has completed Phase I trial for the treatment of cancer cachexia, a disease characterized by an uncontrolled decline in muscle mass. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as other preclinical programs for metabolic diseases and anemia. The company has research collaboration with Kennedy Krieger Institute. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

    [​IMG]
     
  2. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,112
    Likes Received:
    1,570
    Possible pump job on VKTX today
     
  3. KyleLennon

    KyleLennon Member

    Joined:
    Mar 25, 2018
    Messages:
    248
    Likes Received:
    26
    VKTX moved up in response to Madrigal Pharmaceuticals' announcement of successful 36-week results from a Phase 2 study of NonAlcoholic SteatoHepatitis (NASH) candidate MGL-3196, a thyroid hormone receptor-beta agonist. Viking's NASH candidate, Phase 2-stage VK2809, has the same mechanism of action.
     
  4. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,262
    Likes Received:
    1,572
    Wow, I remember stalking this like 1-2 years ago when it was in the 1's
     
  5. AverageJoesTrades

    AverageJoesTrades Well-Known Member

    Joined:
    May 24, 2016
    Messages:
    791
    Likes Received:
    369
    Long @ 9.15 - part of my penny poppers group.
     
  6. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,112
    Likes Received:
    1,570
    Well hello there!
     
  7. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,112
    Likes Received:
    1,570
    Back in the headlines today, check out that open.
     

Share This Page